India · Delayed Price · Currency is INR Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 259.19 billion. The enterprise value is 302.76 billion.
| Market Cap | 259.19B |
| Enterprise Value | 302.76B |
Important Dates
The next confirmed earnings date is Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Piramal Pharma has 1.33 billion shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 1.33B |
| Shares Outstanding | 1.33B |
| Shares Change (YoY) | +0.01% |
| Shares Change (QoQ) | +5.91% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 21.71% |
| Float | 614.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 103.08 |
| PS Ratio | 2.82 |
| PB Ratio | 3.18 |
| P/TBV Ratio | 6.45 |
| P/FCF Ratio | 33.99 |
| P/OCF Ratio | 15.68 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.19, with an EV/FCF ratio of 39.70.
| EV / Earnings | n/a |
| EV / Sales | 3.29 |
| EV / EBITDA | 30.19 |
| EV / EBIT | 140.09 |
| EV / FCF | 39.70 |
Financial Position
The company has a current ratio of 1.51, with a Debt / Equity ratio of 0.70.
| Current Ratio | 1.51 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 6.05 |
| Debt / FCF | 7.49 |
| Interest Coverage | 0.46 |
Financial Efficiency
Return on equity (ROE) is -4.00% and return on invested capital (ROIC) is 1.26%.
| Return on Equity (ROE) | -4.00% |
| Return on Assets (ROA) | 0.36% |
| Return on Invested Capital (ROIC) | 1.26% |
| Return on Capital Employed (ROCE) | 0.72% |
| Weighted Average Cost of Capital (WACC) | 5.88% |
| Revenue Per Employee | 12.93M |
| Profits Per Employee | -440,492 |
| Employee Count | 7,120 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.33 |
Taxes
In the past 12 months, Piramal Pharma has paid 2.09 billion in taxes.
| Income Tax | 2.09B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.18% in the last 52 weeks. The beta is 0.34, so Piramal Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -3.18% |
| 50-Day Moving Average | 206.83 |
| 200-Day Moving Average | 175.92 |
| Relative Strength Index (RSI) | 39.15 |
| Average Volume (20 Days) | 2,405,781 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 92.05 billion and -3.14 billion in losses. Loss per share was -2.36.
| Revenue | 92.05B |
| Gross Profit | 54.69B |
| Operating Income | 1.58B |
| Pretax Income | -1.05B |
| Net Income | -3.14B |
| EBITDA | 8.98B |
| EBIT | 1.58B |
| Loss Per Share | -2.36 |
Balance Sheet
The company has 13.55 billion in cash and 57.12 billion in debt, with a net cash position of -43.57 billion or -32.77 per share.
| Cash & Cash Equivalents | 13.55B |
| Total Debt | 57.12B |
| Net Cash | -43.57B |
| Net Cash Per Share | -32.77 |
| Equity (Book Value) | 81.63B |
| Book Value Per Share | 61.50 |
| Working Capital | 24.33B |
Cash Flow
In the last 12 months, operating cash flow was 16.53 billion and capital expenditures -8.90 billion, giving a free cash flow of 7.63 billion.
| Operating Cash Flow | 16.53B |
| Capital Expenditures | -8.90B |
| Depreciation & Amortization | 7.40B |
| Net Borrowing | 2.83B |
| Free Cash Flow | 7.63B |
| FCF Per Share | 5.74 |
Margins
Gross margin is 59.41%, with operating and profit margins of 1.72% and -3.41%.
| Gross Margin | 59.41% |
| Operating Margin | 1.72% |
| Pretax Margin | -1.14% |
| Profit Margin | -3.41% |
| EBITDA Margin | 9.75% |
| EBIT Margin | 1.72% |
| FCF Margin | 8.60% |
Dividends & Yields
Piramal Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.01% |
| Shareholder Yield | -0.01% |
| Earnings Yield | -1.25% |
| FCF Yield | 2.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Piramal Pharma is 236.45, which is 25.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 236.45 |
| Price Target Difference | 25.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 14.06% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |